Citations

Showing 10 of 108083 citations.

Risk Factors for Recalcitrant Chronic Rhinosinusitis in Organ Transplant Recipients
Candelo, Estephanía , Avila‐Castano, Karol , Verez, Abigail, Vaamonde, Jorge Andrés Abello , Donaldson, Angela M. , Abello-Vaamonde, Jorge A, Gomez, Estephania Candelo , Donaldson, Angela M

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 27, 2023 | Volume: 168 | Issue: 5 | Pages: 1217-1227

10.1002/ohn.236 | PMID 36939492 Get It

AbstractObjectiveStudies suggest that transplant patients are at risk for chronic rhinosinusitis (CRS). However, there is limited information in the literature regarding frequency and reasons for failure of adequate medical therapy. We aim to determine the risk factors associated with the development of medically recalcitrant CRS requiring endoscopic sinus surgery (ESS).Study DesignRetrospective cohort.SettingMayo Clinic.MethodsThis is a retrospective chart review of 925 transplant recipients seen at Mayo Clinic between 2017 and 2022. Inclusion criteria: (1) a rhinologic consultation after transplant and (2) clinical diagnosis of CRS. A total of 549 patients met the inclusion criteria and were divided based on the need for ESS versus successful treatment with medical therapy. Univariate and logistic regression analyses were performed to identify risk factors and predictive variables related to failure of medical therapy.ResultsOf the 549 patients, 201/549 (37%) had medically recalcitrant disease requiring ESS, while 348/549 (63%) were successfully treated with medical therapy Based on logistic regression, patients with recurrent acute rhinosinusitis in the pretransplant period were 8.68 more likely to have a recalcitrant disease (95% confidence interval, 3.72‐20.28, p < 0.0001). Some of the largest determinants of medical therapy failure in the posttransplant period were CRS with nasal polyps, odontogenic CRS, and noninvasive fungal sinusitis. The presence of neutropenia, aplastic anemia, and living transplant were also associated with medically recalcitrant CRS requiring ESS.ConclusionOur predictive model identifies with high accuracy the patients who may be at risk of developing recalcitrant CRS in the organ transplant population.
A drop in heart rate and cardiac output during cardiopulmonary stress testing in a patient with a dual chamber pacemaker
Zaworski, Emelyn, Atwood, Thomas , Janot, Jeffrey M., Vaidya, Vaibhav R. , Allison, Thomas G. , Holmes, David R. , Calvin, Andrew D. , Vaidya, Vaibhav , Calvin, Andrew D , Atwood, Thomas

Mayo Clinic

Pacing and Clinical Electrophysiology | January 27, 2023 | Volume: 46 | Issue: 7 | Pages: 693-696

10.1111/pace.14663 | PMID 36705082 Get It

End-Of-Life Care for Patients With End-Stage Heart Failure, Comparisons of International Guidelines
Rivera, Frederick Berro , Choi, Sarang , Carado, Genquen Philip , Adizas, Arcel V. , Bantayan, Nathan Ross B. , Loyola, Gerard Jude Ponce , Whoy, Sung , Aparece, John Paul , Rocha, Anlene Jane B., Placino, Siena , Ansay, Marie Francesca Mapua, MANGUBAT, GERARD FRANCIS , Mahilum, Mer Lorraine P., Suleman, Natasha, Suboc, Tisha, Cha, Sung Whoy , Al-Abcha, Abdullah, Al‐Abcha, Abdullah , Shah, Nishant , Santos Volgman, Annabelle

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | January 27, 2023 | Volume: 41 | Issue: 1 | Pages: 87-98

10.1177/10499091231154575 | PMID 36705612 Get It

Heart failure (HF) is a chronic, debilitating condition associated with significant morbidity, mortality, and socioeconomic burden. Patients with end-stage HF (ESHF) who are not a candidate for advanced therapies will continue to progress despite standard medical therapy. Thus, the focus of care shifts from prolonging life to controlling symptoms and improving quality of life through palliative care ( PC). Because the condition and prognosis of HF patients evolve and can rapidly deteriorate, it is imperative to begin the discussion on end-of-life (EOL) issues early during HF management. These include the completion of an advance directive, do-not-resuscitate orders, and policies on device therapy and discontinuation as part of advance care planning (ACP). ESHF patients who do not have indications for advanced therapies or those who wish not to have a left ventricular assist device (LVAD) or heart transplant (HT) often experience high symptom burden despite adequate medical management. The proper identification and assessment of symptoms such as pain, dyspnea, nausea, depression, and anxiety are essential to the management of ESHF and may be underdiagnosed and undertreated. Psychological support and spiritual care are also crucial to improving the quality of life during EOL. Caregivers of ESHF patients must also be provided supportive care to prevent compassion fatigue and improve resilience in patient care. In this narrative review, we compare the international guidelines and provide an overview of end-of-life and palliative care for patients with ESHF.
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis
Ali, Ahmad H. , Buness, Cynthia W. , Fischer, Ryan , Holtmann, Gerald , Shah, Ayesha , Lewindon, Peter , Shah, Shamita B. , Ragnekar, Amol S. , Taylor, Amy , Goel, Aparna , Cox, Kenneth L. , Alrabadi, Leina , Wadsworth, Steve , Lindor, Keith D. , Holtmann, Gerald J , Shah, Shamita , Taylor, Amy E , Kulkarni, Sakil S , Lindor, K D , Goel, Aparna

Mayo Clinic

Hepatology | January 27, 2023 | Volume: 77 | Issue: 6 | Pages: E174-E175

10.1097/hep.0000000000000304 | PMID 36705026 Get It

Early administration of SARS‐CoV‐2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID‐19
Jabr, Ra’ed , Khatri, Akshay , Anderson, Anthony D. , Garcia, Leopoldo Cordova, Viotti, Julia Bini , Natori, Yoichiro , Raja, Mohammed , Camargo, José F. , Morris, Michele I. , Khatri, Akshay M , Natori, Yoichiro , Garcia, Leopoldo A. Cordova

Mayo Clinic

Transplant Infectious Disease | January 27, 2023 | Volume: 25 | Issue: 1 | Pages: No page available

10.1111/tid.14006 | PMID 36704987 Get It

AbstractBackgroundData on severe acute respiratory distress syndrome coronavirus 2 monoclonal antibody (SARS‐CoV‐2‐specific mAb) use in hematologic malignancy and hematopoietic cell transplantation (HM/HCT) patients are limited. Here, we describe our experience with the use of casirivimab–imdevimab or bamlanivimab for the treatment of coronavirus disease 2019 (COVID‐19) in HM/HCT patients.MethodsThis was a retrospective chart review at the University of Miami Hospital and Sylvester Comprehensive Cancer Center for HM/HCT patients with COVID‐19 who received casirivimab–imdevimab or bamlanivimab from November 21, 2020, to September 30, 2021. Outcomes measured were mortality, hospital admission, and infusion reaction to SARS‐CoV‐2‐specific mAbs.ResultsWe identified 59 HM/HCT patients with mild to moderate COVID‐19 who received casirivimab–imdevimab or bamlanivimab. Median age was 57 years (interquartile range [IQR]: 45–65). Among the 59 patients, 25 (42%) received cellular therapy: 14 (24%) had undergone allogeneic HCT, nine (15%) autologous HCT, and two (3%) received chimeric antigen receptor T‐cell therapy. The median time from COVID‐19 symptom onset to SARS‐CoV‐2‐specific mAb administration was 4 (IQR: 3–6) days. Forty‐six (78%) patients received SARS‐CoV‐2‐specific mAbs as outpatients and 13 (22%) patients received SARS‐CoV‐2‐specific mAbs during hospitalization. Among patients who received SARS‐CoV‐2‐specific mAbs as outpatients, only four (9%) visited the emergency department at days 10, 11, 15, and 35 after SARS‐CoV‐2‐specific mAb administration. None of these four patients required hospital admission. Among the hospitalized patients, five (38%) were admitted to the hospital with neutropenic fever, four (31%) were already hospitalized for transplantation and cellular therapy, three (23%) were admitted for monitoring of COVID‐19 symptoms, and one (8%) was admitted with acute kidney injury. Three hospitalized patients (23%) died at 14, 35, and 59 days after SARS‐CoV‐2‐specific mAb administration; two of these three deaths were attributed to COVID‐19 infection. One patient developed an immediate infusion reaction to bamlanivimab, and no infusion reactions were reported to casirivimab–imdevimab use.ConclusionDuring the alpha and delta variant surges, early administration of bamlanivimab or casirivimab–imdevimab prevented hospitalization and death when given in the outpatient setting. Among patients who received mAbs at or after hospital admission, the risk of COVID‐19 disease progression and death remains significant. Larger studies of the use of mAb therapy to treat COVID‐19 in this population are needed. image
Paralysis of the Left Hemidiaphragm With Organ Distortion
Zheng, Ting , Camilleri, Michael

Mayo Clinic

American Journal of Gastroenterology | January 27, 2023 | Volume: 118 | Issue: 7 | Pages: 1117-1117

10.14309/ajg.0000000000002197 | PMID 36705492 Get It

Recurrent pleural effusion from ovarian hemangioma: A rare pseudo‐Meigs syndrome presentation
Neshat, Sina , Lee‐Mateus, Alejandra Yu , Fernandez‐Bussy, Isabel, Walsh, Katherine, Walsh, Katherine L, Yu Lee-Mateus, Alejandra , Fernandez-Bussy, Isabel , Abia‐Trujillo, David

Mayo Clinic

Respirology Case Reports | January 27, 2023 | Volume: 11 | Issue: 2 | Pages: No page available

10.1002/rcr2.1087 | PMID 36721846 Get It

AbstractPleural effusion is a common condition related to various diseases such as heart failure, malignancies, and pneumonia. Ovarian hemangioma is a rare type of female genital tumour and can rarely cause pleural effusion. In this case, we present a 48‐year‐old female with repeated episodes of recurrent right‐sided pleural effusion over 1 year with no clear aetiology. Abdominal computed tomography revealed a large left ovarian mass. After surgical removal of the mass, the repeated pleural effusion episodes ceased, and histopathology analysis reported a rare ovarian hemangioma. Pseudo Meigs' syndrome is a triad of an ovarian tumour, ascites, and hydrothorax that rarely presents with ovarian hemangioma; both effusions are eradicated after removing the tumour.
Brow and Eyelid Rejuvenation: Trends from the 100 Most Cited Articles over 30 Years
Salinas, Cristina A., Kirk, Daniel S., Wong, Chin‐Ho , Sharaf, Basel , Sharaf, Basel A, Sharaf, Basel A , Kuruoglu, Doga

Mayo Clinic

Medicina | January 27, 2023 | Volume: 59 | Issue: 2 | Pages: 230

10.3390/medicina59020230 | PMID 36837432 Get It

Background and Objective: Various periorbital rejuvenation techniques have been introduced over the last 3 decades. This study highlights important milestones in the evolution of periorbital rejuvenation surgery by identifying the 100 most-cited articles in this field. Material and Methods: The Web of Science citation index was used to identify the 100 most-cited articles concerning periorbital rejuvenation. Articles published in English from January 1989–April 2020 describing periorbital rejuvenation-related surgical techniques, facial aging, and anatomy were included. The terms “lower blepharoplasty”, “upper blepharoplasty”, “browlift”, “browplasty”, “endobrow lift”, “endoscopic brow”, “Foreheadplasty”, “lower eyelid anatomy”, “upper eyelid anatomy”, “forehead lift”, “eyelid rejuvenation”, “canthopexy”, “canthoplasty”, “eyelid fat pad”, “orbital fat pad”, “tear trough”, and “eyelid bags” were entered into the citation search. Web of Science Core Collection was the database used for the search. A manual review of the initial 159 studies was performed. Articles describing reconstructive or non-invasive techniques, injectable fillers, lasers, and neurotoxins were excluded. Of the 100 most-cited articles, the publication year, specialty journal, the corresponding author’s primary specialty, the focus of the article, the corresponding author’s country of residence, the type of study, and the level of evidence were analyzed. Results: The mean number of citations per article was 75 ± 42. There were more articles published from 1989–1999 (n = 53) than later decades. Most articles originated from the USA (n = 82) and were published in plastic surgery journals (n = 81). Plastic surgery was the primary specialty of the corresponding authors (n = 71), followed by oculoplastic surgery (n = 22). Most articles (n = 69) reported on surgical techniques. Of the clinical studies (n = 69), 45 (79%) provided level IV evidence. Conclusions: Of the 100 most-cited studies on periorbital rejuvenation, studies focusing on periorbital anatomy, aging, and surgical techniques comprised the most-cited publications. An anatomically based approach accounting for age-related changes in the periorbital structures is paramount in the field of contemporary periorbital rejuvenation.
An In-Depth Analysis of Providers and Services of Cancellation in Anesthesia Reveals a Complex Picture after Systemic Analysis
Laudański, Krzysztof , Wain, Justin, Pizzini, Mark‐Alan

Mayo Clinic

Healthcare | January 27, 2023 | Volume: 11 | Issue: 3 | Pages: 357

10.3390/healthcare11030357 | PMID 36766932 Get It

The variances in operating room (OR) cancellation rates between different service lines and operators within these service lines were assessed by reviewing the electronic medical record (EMR) covering 34,561 cases performed by 199 OR operators in 2018. We assumed that cancellations would differ between different service lines, but the between-operators variance was minimal within the service line. We hypothesized that most variability would be secondary to patient-specific (weekdays, time of year, and national holidays), seasonal and administrative issues. Of 4165 case cancellations, the majority (73.1%) occurred before the patient arrived at the hospital. A total of 60% of all cancellations were within gastroenterology, interventional cardiology, and orthopedics. Cancellation rate variability between surgeons operating within the same service line greatly varied between services from very homogenous to very diverse across providers. The top reasons for cancellation were: date change, canceled by a patient, or “no show”. The highest cancellation rates occurred on Mondays and Tuesdays, in January and September, and during weeks associated with national holidays. In summary, cancellation variability must be analyzed at the level of individual specialties, operators, and time variability.
Novel insights into the phenotype and long-term D-gal treatment in PGM1-CDG: a case series
Radenkovic, Silvia , Johnsen, Christin , Lail, Gurnoor , Guilder, Laura, Schwartz, Kaitlin, Boyer, Suzanne, Schultz, Matthew, Boyer, Suzanne , Schulze, Andreas , Schultz, Matthew , Mercimek‐Andrews, Saadet , Morava, Éva

Mayo Clinic

Therapeutic Advances in Rare Disease | January 27, 2023 | Volume: 4 | Issue: No issue available | Pages: No page available

10.1177/26330040221150269 | PMID 37181075 Get It

Phosphoglucomutase-1-congenital disorder of glycosylation (PGM1-CDG) (OMIM: 614921) is a rare autosomal recessive inherited metabolic disease caused by the deficiency of the PGM1 enzyme. Like other CDGs, PGM1-CDG has a multisystemic presentation. The most common clinical findings include liver involvement, rhabdomyolysis, hypoglycemia, and cardiac involvement. Phenotypic severity can vary, though cardiac presentation is usually part of the most severe phenotype, often resulting in early death. Unlike the majority of CDGs, PGM1-CDG has a treatment: oral D-galactose (D-gal) supplementation, which significantly improves many aspects of the disorder. Here, we describe five PGM1-CDG patients treated with D-gal and report both on novel clinical symptoms in PGM1-CDG as well as the effects of the D-gal treatment. D-gal resulted in notable clinical improvement in four patients, though the efficacy of treatment varied between the patients. Furthermore, there was a significant improvement or normalization in transferrin glycosylation, liver transaminases and coagulation factors in three patients, creatine kinase (CK) levels in two, while hypoglycemia resolved in two patients. One patient discontinued the treatment due to urinary frequency and lack of clinical improvement. Furthermore, one patient experienced recurrent episodes of rhabdomyolysis and tachycardia even on higher doses of therapy. D-gal also failed to improve the cardiac function, which was initially abnormal in three patients, and remains the biggest challenge in treating PGM1-CDG. Together, our findings expand the phenotype of PGM1-CDG and underline the importance of developing novel therapies that would specifically treat the cardiac phenotype in PGM1-CDG.